Answers are grounded in this paper and cite their sources.
Development report details a continuous synthesis method for a RIPK1 inhibitor, improving efficiency over prior techniques.
A three-step synthesis of the core of the investigational RIPK1 inhibitor oditrasertib (DNL788, SAR443820) is described. This route features a telescoped three-step sequence enabled by continuous flow and a single crystallization to isolate the target bromopyridine in 68% overall yield and excellent purity (greater than 99.5% by weight percent and LCAP). The telescoped continuous process showed significant improvements in efficiency compared with the prior batch manufacturing route.
No takes yet. Share an insight, caveat, or question.
Ahlqvist et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: